Permanent disabilities in childhood survivors of Langerhans cell histiocytosis.
This study evaluates the permanent disabilities in children treated for Langerhans cell histiocytosis (LCH). From January 1983 to December 1993, 50 patients with newly diagnosed biopsy proven LCH were seen at the Regional Cancer Centre, Trivandrum, India. Disease pattern, treatment, survival, and disabilities of the patients were studied. Patients with localized disease had surgery, irradiation, or steroids. Patients with disseminated disease had combination chemotherapy. Follow-up ranged from 36 to 156 months (median follow-up 85 months). Twelve of the 41 surviving patients (29.2%) had one or more disabilities. Growth retardation was seen in 8 patients, diabetes insipidus in 7, loss of teeth in 6, and mandibular defect, chronic aural discharge, partial hearing loss, facial palsy, and proptosis in 2 each. In short, a significant proportion of survivors of LCH had sequelae, which affected their quality of life. More intensive chemotherapy at the beginning might be helpful in reducing the disabilities.
Kusumakumary
P
P
Department of Pediatric Oncology, Regional Cancer Centre, Trivandrum, India. rcctvm@md2.vsnl.net.in
James
F V
FV
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D002658:Developmental Disabilities / Q000209:etiology* / Q000473:pathology; D003919:Diabetes Insipidus / Q000209:etiology / Q000628:therapy; D004185:Disability Evaluation; D005500:Follow-Up Studies; D006130:Growth Disorders / Q000209:etiology / Q000473:pathology / Q000628:therapy; D006646:Histiocytosis, Langerhans-Cell / Q000150:complications* / Q000401:mortality; D006801:Humans; D011788:Quality of Life; D012189:Retrospective Studies; D015996:Survival Rate